Andere Sprachen Clearmind Medicine Inc.

Aktien

A3E2CG

CA1850534027

CMND

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.07.2024			% 5 Tage	% 1. Jan.
1,66 ^USD	-1,19 %		+23,88 %	-40,93 %

20.06.	Clearmind Medicine sichert sich die weltweiten Exklusivrechte an innovativen psychedelischen Wirkstoffen zur Behandlung von PTSD	CI
13.06.	Clearmind Medicine Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. April 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment	28.06.
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	20.06.
Clearmind Medicine Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	20.06.
Clearmind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	13.06.
Clearmind Medicine : Condensed Interim Consolidated Financial Statements Form 6 K	13.06.
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink	11.06.
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	13.05.
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10.05.
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10.05.
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07.05.
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07.05.
Clearmind Applies to Cease Being a Reporting Issuer in Canada	30.04.
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17.04.
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10.04.
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10.04.
Clearmind Medicine CEO Issues Letter to Shareholders	09.04.
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27.03.
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	19.03.
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	19.03.
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clearmind Medicine Inc.

Aktien

A3E2CG

CA1850534027

CMND

Andere Sprachen

Filter